Updated

June 6, 2020: I posted Part 2 with supplementary details confirming that the proposed experimental “vaccine” is using a cell line from human fetal tissue.

Health Canada approves human trial testing of coronavirus vaccine derived from aborted fetal cell line by Anthony Murdoch | Lifesitenews.com | May 19, 2020

The vaccine candidate Ad5-nCoV uses the HEK293 cell line that LifeSiteNews reported last week is made from fetal cells harvested from an aborted baby decades ago. The HEK293 cell line was developed and is owned by Canada’s National Research Council (NRC).

On May 12, the NRC announced a collaboration with the Chinese firm CanSino Biologics Inc. (CanSinoBIO) to test and develop Ad5-nCoV in Canada. . . . co-developed by the Beijing Institute of Biotechnology . . .

Alan Moy, M.D., founder and scientific director of the John Paul II Medical Research Institute and CEO of Cellular Engineering Technologies, confirmed . . .

“Since it’s using an adenovirus replication-defective vector, it is using HEK293. . . . “

---

Moy identified it as using HEK293, which is catalogued:
https://www.hek293.com/
https://www.atcc.org/products/all/CRL-1573.aspx
https://en.wikipedia.org/wiki/HEK_293_cells

---

Canada’s first COVID-19 vaccine trials approved for Halifax university | cbc.ca | May 16, 2020

. . . The trials have been approved by Health Canada and will take place at the Canadian Centre for Vaccinology (CCfV) at Dalhousie University in Halifax.

. . . He [Trudeau] added the National Research Council will be working with the manufacturers so that if these vaccine trials are successful, the vaccine can be produced and distributed “here at home.”

The CCfV team of about 45 people is working with a potential vaccine from Chinese company CanSino Biologics.

. . . Scott Halperin, director of the CCfV and a professor of pediatrics, microbiology and immunology at Dalhousie University, said they are building on trials that have already begun in China.

The vaccine strain, called Ad5-nCoV, uses another virus that’s been modified so it can’t cause infection in humans, he said. It expresses one of the COVID-19 antigens on its surface called the “spike protein.”

. . . When they move into Phase 2, likely in a couple months, they will be joined by multiple centres across the country through the Canadian Immunization Research Network (CIRN).

It’s not the only vaccine being tested.

He actually says that

Health Canada could allow the vaccine to be used before that [the normal approval stage] in an “emergency release“

---

How the first Canadian COVID-19 vaccine trial will work by Ryan Flanagan | CTVNews.ca | May 17, 2020

Halperin is the director of the Canadian Center for Vaccinology at Dalhousie University in Halifax, which has been approved to begin trials of the vaccine candidate known as Ad5-nCoV.

DOUBLE THINK:

He said that due to the nature of the COVID-19 pandemic, his team will carry out tests “in a more accelerated fashion, without sacrificing any safety,” by not waiting for full results from one stage of their research before moving on to the next.

---

My research on current Canadian-approved vaccines, identifying some as containing human fetal tissue–and it means that everyone needs to reconsider their position on allowing their children to be vaccinated also: https://canadianliberty.com/vaccine-documents-part-2-human-cells-from-aborted-babies/

---